Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The major aim of this study was to evaluate the performance of anti-BRAF V600E (VE1) antibody in colorectal tumors with and without KRAS mutation.
|
29127628 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A tissue microarray containing colorectal tumors was used to study the relationship between KRAS mutations and c-Met expression.
|
30412912 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Implications: This model is an excellent preclinical platform to molecularly characterize the KRAS mutated colorectal tumors and discern appropriate therapeutic strategies to improve disease management and overall survival.
|
31766149 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The proto-oncogene KRAS belongs among the most frequently mutated genes in all types of cancer and is also very important oncogene related to colorectal tumors.
|
30661213 |
2019 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In conclusion, deregulated energy metabolism has a close relationship with KRAS mutations in colorectal tumors.
|
30362665 |
2018 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The SNaPshot analysis detected KRAS c35 mutations in colorectal tumor tissue in 14 cases, but the presence of the mutation was not confirmed in cfDNA extracted from blood samples of these patients.
|
28365952 |
2017 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We sought to identify a KRAS-associated gene signature from colorectal tumors to develop a precise treatment strategy.
|
28459468 |
2017 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.
|
27289420 |
2016 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
|
27352204 |
2016 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
APC and KRAS were mutated at significantly lower rates in tumors from patients with IBD than in sporadic colorectal tumors (13% and 20% of cases, respectively).
|
26764183 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Given the reported association of increased body mass index (BMI) and low-level physical activity with KRAS-mutated colorectal tumor, we hypothesized that low-level plasma adiponectin might be associated with increased risk of KRAS-mutant colorectal carcinoma but not with risk of KRAS wild-type carcinoma.
|
26598515 |
2016 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
KRAS mutations are present in 40% of colorectal tumors and monitoring the mutational status together with the level of mutated DNA is of great interest.
|
25446878 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors.
|
26028667 |
2015 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In two further cases localization, histological type and KRAS mutational status all supported the occurrence of synchron/metachron colorectal tumors.
|
25248721 |
2015 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
|
26623049 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We evaluated 130 colorectal tumors for mutations in KRAS and NRAS gene.
|
25997687 |
2015 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We found that K-Ras4A was widely expressed in 30 of 30 human cancer cell lines and amounts equal to K-Ras4B in 17 human colorectal tumors.
|
25561545 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Moreover, ethnic or geographic factors may have an impact on genetic background of colorectal carcinomas, and specific types of KRAS mutations may influence the metastatic potential of colorectal tumors.
|
26681025 |
2015 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The failure of EGFR inhibitors in colorectal tumors with KRAS mutations requires the development of alternative treatment strategies for this patient subgroup.
|
24351336 |
2014 |
Colorectal Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.
|
24558511 |
2014 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To study further with an independent cohort, data from The Cancer Genome Atlas were analyzed to define a gene expression signature for patients whose tumors feature these atypical RAS mutations and explore differences with KRAS 12/13-mutated colorectal tumors.
|
25009008 |
2014 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However, genomic, epigenomic and molecular pathology testings (for example, analyses for microsatellite instability, MLH1 promoter CpG island methylation, and KRAS and BRAF mutations in colorectal tumors) are becoming routine clinical practices.
|
23792451 |
2014 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression.
|
25280562 |
2014 |